BioCorRx Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioCorRx Inc. | ||
| Date: March 31, 2025 | By: | /s/ Lourdes Felix |
|---|---|---|
| Lourdes Felix | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Lourdes Felix | Chief Executive Officer, Chief Financial Officer, and Director | March 31, 2025 |
| Lourdes Felix | (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer) | |
| /s/ Kent Emry | Director | March 31, 2025 |
| Kent Emry | ||
| /s/ Luisa Ingargiola | Director | March 31, 2025 |
| Luis Ingargiola | ||
| /s/ Louis Lucido | Director, Interim President from January 5, 2024 to January 31, 2024, and President effective on February 1, 2024 | March 31, 2025 |
| Louis Lucido | ||
| /s/ Joseph J. Galligan | Director | March 31, 2025 |
| Joseph J. Galligan | ||
BIOCORRX, INC.
CONSOLIDATED FINANCIAL STATEMENTS
TABLE OF CONTENTS
| Report of Independent Registered Public Accounting Firms (PCAOB ID 2738 and 688) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Deficit for the Years Ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.